Objective Preclinical evaluation of neuroprotectants fostered high expectations of clinical
efficacy. When not matched, the question arises whether experiments are poor indicators of …

Correctable weaknesses in the design, conduct, and analysis of biomedical and public
health research studies can produce misleading results and waste valuable resources. Small …

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting
from chemotherapy for cancer. Severe acute CIPN may require chemotherapy dose …

The US National Institute of Neurological Disorders and Stroke convened major stakeholders
in June 2012 to discuss how to improve the methodological reporting of animal studies in …

… Macleod … Sena E, Van der Worp HB, Howells D, Macleod M (2007) How can we
improve the pre-clinical development of drugs for stroke? Trends Neurosci 30: 433–439 …

Stroke is the second highest cause of death globally and a leading cause of disability, with
an increasing incidence in developing countries. Ischaemic stroke caused by arterial …

Comment 102 www. thelancet. com Vol 383 January 11, 2014 from governments, which are
run, at least partly, by politicians. The success of funding policy, and the job security of the …

Background and Purpose— The extensive neuroprotective literature describing the efficacy
of candidate drugs in focal ischemia has yet to lead to the development of effective stroke …

The consolidation of scientific knowledge proceeds through the interpretation and then
distillation of data presented in research reports, first in review articles and then in textbooks and …

Induced hypothermia is proposed as a treatment for acute ischaemic stroke, but there have
been too few clinical trials involving too few patients to draw any conclusions about the …